This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (16)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ethel Tur, MD; Sarah Brenner, MD; M. Landau, MD; H. Golan, MD

Arch Dermatol. 1996;132(3):327-331.

Abstract
The classic form of Kaposi's sarcoma (KS) is a rare multifocal neoplasm, as described by Kaposi in 1872.¹ One hundred nine years after Kaposi's first description of the disease, the interest in all aspects of this disease escalated because of the emergence of human immunodeficiency virus (HIV), which is frequently accompanied by KS. This prompted zealous research, as reflected by numerous reports. Despite recent important discoveries,² we are still far from understanding the pathogenesis of the disease and the mechanism of action of its various treatment modalities. As of today, treatment consists of most of the old modalities, some old ones in an updated improved version, and some new and experimental therapies. Our purpose is to focus on recent or novel data and to mention available treatments and their advantages, di vantages, and side effects. We will also speculate on future directions.

Author Affiliations
Tel Aviv, Israel

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Classic Kaposi's Sarcoma Associated with Human Herpesvirus 8 Infection in a 13-Year-Old Male: A Case Report
Landau et al.
Clin. Cancer Res. 2001;7:2263-2268.
ABSTRACT | FULL TEXT  

Isolated Limb Perfusion With High-Dose Tumor Necrosis Factor {alpha} and Melphalan for Kaposi Sarcoma
Lev-Chelouche et al.
Arch Surg 1999;134:177-180.
ABSTRACT | FULL TEXT  

Recombinant Interleukin 2 Monotherapy for Classic Kaposi Sarcoma
Shibagaki et al.
Arch Dermatol 1998;134:1193-1196.
FULL TEXT